Tumori最新文献

{"title":"Breast cancer and large-cell neuroendocrine carcinoma harboring the same <i>PIK3CA</i> mutation: A case report.","authors":"Emma Zattarin, Teresa Beninato, Giorgia Di Liberti, Daniele Lorenzini, Andrea Vingiani, Rita Leporati, Mario Occhipinti, Marta Brambilla","doi":"10.1177/03008916251353357","DOIUrl":"https://doi.org/10.1177/03008916251353357","url":null,"abstract":"<p><strong>Background: </strong>The distinction between a metastatic recurrence and the onset of a second primary malignancy can be diagnostically challenging. Precision medicine can offer valuable support in this context.</p><p><strong>Case presentation: </strong>A 34-year-old woman was diagnosed in 2012 with hormone-receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in the left breast, with homolateral axillary node involvement but no distant metastases. Following neoadjuvant chemotherapy, surgery (pathological stage was ypT1b ypN2a M0), adjuvant endocrine therapy and radiotherapy, she remained disease-free until 2021, when a positron emission tomography scan showed a mediastinal mass. Histology revealed a high-grade large cell neuroendocrine carcinoma (LCNEC) lacking breast cancer-specific markers (GATA3-, HR-, HER2-, mammoglobin-, GCDFP15-), with PD-L1 expression at 10% and a tumor mutational burden (TMB) of 9.54 mut/MB. Chemotherapy (cisplatin plus etoposide) led to rapid disease progression, whereas second-line pembrolizumab led to a remarkable and prolonged disease response. Treatment was discontinued in 2023 due to grade 3 immune-related colitis and, as of November 2024, the patient shows no clinical evidence of disease.Molecular analysis:Next-generation sequencing identified shared tumor <i>PIK3CA</i> pathogenic variants in both breast cancer and LCNEC tissues, suggesting a potential relationship as primary tumor and metastasis, rather than two distinct malignancies.</p><p><strong>Conclusions: </strong>Molecular characterization of cancer enabled the identification of potential causal links between tumors with distinct histologies and locations, offering a deeper insight into an atypical clinical scenario.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251353357"},"PeriodicalIF":2.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A literature review of radio-genomics in breast cancer: Lessons and insights for low and middle-income countries.","authors":"Mehwish Mooghal, Kulsoom Shaikh, Hafsa Shaikh, Wajiha Khan, Muhammad Shiraz Siddiqui, Sara Jamil, Lubna M Vohra","doi":"10.1177/03008916251356446","DOIUrl":"https://doi.org/10.1177/03008916251356446","url":null,"abstract":"<p><p>To improve precision medicine in breast cancer (BC) decision-making, radio-genomics is an emerging branch of artificial intelligence (AI) that links cancer characteristics assessed radiologically with the histopathology and genomic properties of the tumour. By employing MRIs, mammograms, and ultrasounds to uncover distinctive radiomics traits that potentially predict genomic abnormalities, this review attempts to find literature that links AI-based models with the genetic mutations discovered in BC patients. The review's findings can be used to create AI-based population models for low and middle-income countries (LMIC) and evaluate how well they predict outcomes for our cohort.Magnetic resonance imaging (MRI) appears to be the modality employed most frequently to research radio-genomics in BC patients in our systemic analysis. According to the papers we analysed, genetic markers and mutations linked to imaging traits, such as tumour size, shape, enhancing patterns, as well as clinical outcomes of treatment response, disease progression, and survival, can be identified by employing AI. The use of radio-genomics can help LMICs get through some of the barriers that keep the general population from having access to high-quality cancer care, thereby improving the health outcomes for BC patients in these regions. It is imperative to ensure that emerging technologies are used responsibly, in a way that is accessible to and affordable for all patients, regardless of their socio-economic condition.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251356446"},"PeriodicalIF":2.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients.","authors":"Daniele Lorenzini, Gabriella Gaudioso, Alessandro Scardoni, Lorenzo Blandi, Alessandro Del Gobbo, Paola Rafaniello Raviele, Stefano Ferrero, Silvio M Veronese, Calogero Lauricella, Fabio Pagni, Davide Seminati, Monica Miozzo, Chiara Pesenti, Umberto Gianelli, Simona Buiatiotis, Caterina Fumagalli, Elena Guerini Rocco, Alessandra Rappa, Massimo Barberis, Nicola Fusco, Alberto Ranghiero, Stefano La Rosa, Fausto Sessa, Daniela Furlan, Nora Sahnane, Carlo Patriarca, Maria Giulia Cangi, Alessandra Lume, Claudio Doglioni, Maurilio Ponzoni, William Vermi, Mauro Novali, Marco Paulli, Emanuela Boveri, Luigi Terracciano, Silvia Uccella, Annarita Destro, Elena Tamborini, Federica Perrone, Fabio Pasotti, Francesco Agustoni, Filippo De Braud, Francesco Grossi, Salvatore Siena, Giuseppe Curigliano, Sabrina Buoro, Giancarlo Pruneri","doi":"10.1177/03008916251341996","DOIUrl":"https://doi.org/10.1177/03008916251341996","url":null,"abstract":"<p><strong>Background: </strong>Recent advancements in identifying druggable molecular drivers in lung adenocarcinoma (LUAD), have transformed treatment paradigms. In recent years, Next Generation Sequencing (NGS) has gained momentum as an essential tool for in-depth simultaneous analysis of multiple genes, thereby streamlining the diagnostic process in LUAD. Despite this, the implementation of NGS testing in both the US and Europe remains suboptimal.</p><p><strong>Aims: </strong>In compliance with a decree issued by the Italian Ministry of Health, Lombardy Region recently launched an initiative to implement NGS testing in patients with advanced LUAD. In this context, a real-world prospective observational study was planned to assess the efficacy of the regional network of molecular laboratories in testing nine biomarkers (<i>KRAS</i> p.G12C, <i>EGFR</i>, <i>BRAF, HER2, MET</i> mutations; <i>ALK</i>, <i>ROS1</i>, <i>NTRK1-3</i>, <i>RET</i> rearrangements), for on-label molecularly targeted drugs.</p><p><strong>Results: </strong>In 2023, out of the 2784 advanced/metastatic LUAD patients expected in Lombardy, 2343 (84.2%) were successfully evaluated with an NGS panel including all the nine biomarkers for on-label drugs. Actionable aberrations were identified in 45.5% of the patients (1068/2343), predominantly involving <i>EGFR</i>, <i>KRAS</i>, and <i>ALK</i> genes.</p><p><strong>Conclusion: </strong>Our data provide evidence that establishing a structured network of NGS hubs is mandatory to ensure access of advanced LUAD patients to molecularly targeted treatments.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251341996"},"PeriodicalIF":2.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization.","authors":"Daniele Lorenzini, Rebecca Salvatori, Chiara Costanza Volpi, Desirè Viola Trupia, Monica Niger, Federico Nichetti, Matteo Duca, Silvia Damian, Adele Busico, Alessia Bertolotti, Katia Todoerti, Luca Agnelli, Andrea Vingiani, Giancarlo Pruneri","doi":"10.1177/03008916251345409","DOIUrl":"https://doi.org/10.1177/03008916251345409","url":null,"abstract":"<p><strong>Introduction: </strong>Anti-HER2 drugs are becoming an important therapeutic option for various solid tumors, increasing the need for HER2 status testing. Comprehensive genomic profiling (CGP) panels, including FoundationOne®CDx, are commonly used to assess <i>ERBB2</i> (encoding for HER2) copy number alterations. We aimed to evaluate the analytical validity of FoundationOne®CDx assay, by comparing <i>ERBB2</i> copy number data with traditional HER2 status by immunohistochemistry (IHC)/in situ hybridization (ISH) assays in a heterogeneous cohort of solid tumor samples.</p><p><strong>Methods: </strong>We retrospectively reviewed the 531 cases evaluated by FoundationOne®CDx in our Institution, and HER2 status by IHC/ISH could be internally analyzed in 68 cases, including 31 (45.5%) gastroesophageal, 17 (25.0%) colorectal, four (5.8%) breast and two (2.9%) cholangiocarcinoma patients.Tumors with estimated <i>ERBB2</i> copy number ⩾ 4 by FoundationOne®CDx, and tumors with strong and complete (3+) membranous staining by IHC and/or a HER2/CEP17 ratio ⩾2 by ISH were considered NGS positive and IHC/ISH positive, respectively.</p><p><strong>Results: </strong>We identified 21 NGS positive cases (30.9%); IHC/ISH analysis confirming overexpression/amplification in 16 cases (sensitivity: 76.2%), while among the 47 NGS negative cases, 45 were confirmed by IHC/ISH results (specificity: 90%), with a positive predictive value of 76.2% and a negative predictive value of 95.7%.</p><p><strong>Conclusions: </strong>FoundationOne®CDx provides an accurate evaluation of <i>ERBB2</i> copy number status and may represent a cost-effective option in metastatic cancer patients for whom NGS testing is recommended.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251345409"},"PeriodicalIF":2.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia.","authors":"Yan Cheng, Hongwei Wu","doi":"10.1177/03008916251346563","DOIUrl":"10.1177/03008916251346563","url":null,"abstract":"<p><strong>Objective: </strong>Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in approximately 6-10% of acute myeloid leukemia (AML) patients. Ivosidenib (IVO) is a small-molecule inhibitor of mutant IDH1. This study delves into the mechanism of IVO with hypomethylating agents (HMAs) (azacitidine or decitabine) for treating IDH1-mutated AML through the PI3K/AKT pathway.</p><p><strong>Methods: </strong>IDH1^R132H-mutated MOLM-13 (IDH1^R132H-MOLM-13) cells were constructed. The effects of the drugs, both individually and in combination, on IDH1^R132H-MOLM-13 cell proliferation and apoptosis were assessed using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide and flow cytometry, with combination index (CI) values calculated using CompuSyn software. <i>IDH1</i>, <i>DNMT1</i>, <i>PI3K</i> and <i>AKT</i> gene mRNA levels, and the PI3K/AKT pathway- and histone lysine methylation-related protein levels in IDH1^R132H-MOLM-13 cells were determined by RT-qPCR and Western blot.</p><p><strong>Results: </strong>IDH1^R132H-mutated MOLM-13 cells (IDH1^R132H-MOLM-13) were successfully constructed. The IDH1 inhibitor, either as a monotherapy or combined with HMAs, effectively inhibited IDH1^R132H-MOLM-13 cell proliferation, and the combination therapy exhibited synergistic effects (CI < 1). The combination therapy increased cell proportion in the G2/M phase and apoptotic rate. Both treatment modalities reduced <i>IDH1</i>, <i>DNMT1</i>, <i>PI3K</i> and <i>AKT</i> mRNA levels and histone lysine methylation levels (H3K4me3, H3K9me3, H3K27me3); besides, PI3K and AKT phosphorylation levels were reduced, with the reductions being more significant in cells undergoing combination therapy. The indexes did not differ significantly between cells undergoing the two modalities of combined treatments.</p><p><strong>Conclusion: </strong>The IDH1 inhibitor with HMAs suppressed IDH1^R132H-MOLM-13 cell proliferation and viability and decreased the methylation level by repressing the phosphorylation of the PI3K/AKT pathway, showing a synergistic inhibitory effect.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251346563"},"PeriodicalIF":2.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engagement in cancer clinical trials among a nationally representative cancer survivor sample: Motivators, barriers and opportunities for improvement.","authors":"Zachary S Feuer, Richard S Matulewicz, Ramsankar Basak, Donna A Culton, Kimberly Weaver, Kristalyn Gallagher, Hung-Jui Tan, Tracy L Rose, Matthew Milowsky, Marc A Bjurlin","doi":"10.1177/03008916251347175","DOIUrl":"https://doi.org/10.1177/03008916251347175","url":null,"abstract":"<p><strong>Purpose: </strong>Most patients with cancer do not participate in a clinical trial. Understanding clinical participation rates, and the barriers and motivators that influence participation may help identify opportunities for improvement in accrual.</p><p><strong>Methods: </strong>A cross-sectional analysis of cancer survivors was conducted using the Health Information National Trends Survey (HINTS) administered in 2020. Primary outcome was clinical trial participation amongst patients with cancer. Secondary outcomes were motivators and barriers to influence clinical trial participation. Logistic regression was employed to assess the association of clinical trials being discussed as a cancer treatment option with social determinants.</p><p><strong>Results: </strong>Six hundred and eighteen respondents (weighted population estimate 22,723,047) with a self-reported history of cancer were included. Overall, 15.7% reported an invitation to participate in a clinical trial, of which 37.8% participated. Clinical trials were discussed as a cancer treatment option amongst 13.5% of respondents. Knowledge of clinical trials was low (9.3%). Reported motivators included trying new care (72.3%), wanting to get better (88.9%), getting paid (40.1%), helping other people (73.0%), and encouragement from the doctor (73.7%) or family/friends (59.5%). Reported barriers included getting transportation, childcare or paid time off work (42.4%), and standard care not covered by insurance (69.6%). Race (Other, OR 3.84) and income (<$35k, OR 5.84) were associated with discussion of clinical trials as a cancer treatment option.</p><p><strong>Conclusion: </strong>Clinical trial treatment discussion, invitation, and participation are low among patients with a history of cancer. Although the study identified multiple motivators and barriers to participation, improvement in the rates of discussion and invitation to participate in a clinical trial are required. Nevertheless, addressing the identified barriers and motivators that influence clinical trial participation may be a strategy to optimize patient enrollment.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251347175"},"PeriodicalIF":2.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?","authors":"Fausto Petrelli, Antonio Ghidini, Italo Sarno, Alessandro Iaculli, Angeli Irene, Giovanna Moleri, Mauro Rossitto, Lorenzo Dottorini","doi":"10.1177/03008916251328539","DOIUrl":"https://doi.org/10.1177/03008916251328539","url":null,"abstract":"<p><strong>Introduction: </strong>The strategic addition of immune checkpoint inhibitors (ICIs) to chemotherapy (CT) offers a potential paradigm shift in the treatment of elderly cancer patients. This systematic review evaluates the impact of ICIs combined with CT on the overall survival (OS) of patients aged 65 and older.</p><p><strong>Material and methods: </strong>Using the terms \"immune checkpoint inhibitors\" and (PD-1 or PD-L1 or CTLA-4) and (\"cancer\" or \"carcinoma\") and (\"elderly\" or \"older\" or \"65 years\" or \"70 years\"), we searched PubMed, Embase, and the Cochrane Library through March 2024. We selected only English language, phase II-III randomized controlled trials comparing first-line CT + ICIs vs. CT alone for metastatic cancers, with subgroups reporting outcomes of elderly patients (according to the authors' cutoff of at least 65 years). Hazard ratios (HR) for OS with relative 95% confidence intervals (95%CI) were extracted from each study. Summary HR was calculated using random- or fixed-effects models, depending on the heterogeneity of the included studiesResults:The study synthesizes data from 46 phase III randomized controlled trials, focusing on first-line treatments for metastatic cancers, where ICIs plus CT are compared against CT. The meta-analysis reveals that the combination therapy significantly improves OS in certain cancer types like lung cancers (HR=0.79, 95%CI 0.73-0.86; P<0.01), esophageal (HR=0.68, 95%CI 0.6-0.77; P<0.01) and gastric carcinomas (HR=0,8, 95%CI 0.63-0.88; P<0.01). In other cancers, evidence is less strong (e.g, gynecological, breast, genitourinary, head and neck, and skin cancers).</p><p><strong>Conclusions: </strong>These findings suggest that while the addition of ICIs can enhance survival outcomes in a subset of elderly cancer patients, its efficacy is highly contingent upon the cancer type and the specific patient's health profile.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251328539"},"PeriodicalIF":2.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological characteristics and prognosis of cervical adenocarcinoma across diverse histological subtypes.","authors":"Xiaowan Guo, Miao Wang, Sisi Yan, Kehua Hu, Jiaqiang Xiong, Hui Qiu, Qiuji Wu","doi":"10.1177/03008916251341993","DOIUrl":"https://doi.org/10.1177/03008916251341993","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical features and prognostic implications of different subtypes of cervical adenocarcinoma.</p><p><strong>Methods: </strong>We examined 13,353 adenocarcinoma (AC) cases from the SEER database to identify distinct clinical characteristics and prognostic factors among various histological subtypes. Using the WHO classification and International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) codes, we categorized patients and assessed overall survival (OS) and cancer-specific survival (CSS) via Kaplan-Meier and Cox regression analyses. A nomogram was constructed to predict patient survival across subtypes.</p><p><strong>Results: </strong>Patients with non-usual type show a significantly poorer prognosis. Our analysis revealed that serous carcinoma patients had the most adverse outcomes (OS: hazard ratio (HR) = 2.69, 95% confidence interval (CI): 2.23-3.23, P < 0.001; CSS: HR = 1.78, 95% CI: 1.34-2.36, P < 0.001), while villous adenocarcinoma patients had the most favorable (OS: HR = 0.43, 95% CI: 0.29-0.65, P < 0.001; CSS: HR = 0.32, 95% CI: 0.17-0.60, P < 0.001), compared to the usual type. Multivariable Cox regression identified age, marital status, race, tumor grade, FIGO stage, and treatment as independent prognostic factors. In patients with serous carcinoma, advanced FIGO stage was a risk factor (stage IV vs stage I: HR = 4.06, 95% CI: 1.35-12.22, P = 0.013), and surgery was a protective factor (HR = 0.22, 95% CI: 0.10-0.49, P < 0.001). We also created a prognostic model incorporating diverse histological subtypes, internally validated for high predictive accuracy and discrimination via the receiver operating characteristic (ROC) curve and calibration plots.</p><p><strong>Conclusion: </strong>Clinical characteristics and prognostic features in cervical adenocarcinoma vary significantly by histological subtype, with serous carcinoma being associated with the worst outcomes.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251341993"},"PeriodicalIF":2.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ongoing discussion: Is prophylactic central neck dissection necessary in _cT_1a-b,2N₀ papillary thyroid cancer?","authors":"Ömer Bayır, Latif Akan, Muhammed Kızılgül, Bekir Uçan, Sevilay Karahan, Gökhan Toptaş, Şevket Aksoy, Esra Nur Bayır, Muhammed Erkam Sencar, Erman Çakal, Güleser Saylam, Mehmet Hakan Korkmaz","doi":"10.1177/03008916251334884","DOIUrl":"https://doi.org/10.1177/03008916251334884","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the central lymph node metastasis (CLNM) rates of patients who underwent prophylactic central lymph node dissection (pCLND) with total thyroidectomy for cT1-2N0 papillary thyroid cancer in our clinic, to evaluate the conditions associated with lymph node metastasis, and to examine the necessity of pCLND in these patient groups.</p><p><strong>Methods: </strong>This study includes a retrospective review of the medical data of patients who underwent bilateral/unilateral central lymph node dissection (CLND) (b/uCLND) with total thyroidectomy in our center between 2013 and 2021, whose fine needle aspiration biopsy result was reported as malignant, who were detected as cT1a-1b-2N0 on thyroid and neck ultrasonography.</p><p><strong>Results: </strong>Of the 251 patients included in the study, 63 (25%) had CLNM (49 (19.5%) ipsilateral and 14 (5.5%) had contralateral CLNM). Twenty-two (20.1%) of 109 patients with cT1a, 30 (28.3%) of 106 patients with cT1b, and 11 (30.5%) of 36 patients with cT2 had CLNM, and metastasis rates increased with increasing cT category. CLNM rates increased with increasing pT category (p=0.005). CLNM was present in 21 (38.8%) of 54 patients (21.5%) with collision tumors, and metastasis rates increased significantly compared to the presence of a single histopathologic tumor (p=0.006). CLNM rates were higher in patients with multicentric tumor localization than in those with unicentric localization (p=0.006).</p><p><strong>Conclusion: </strong>Multicentricity, bilaterality, capsule invasion, collision tumors and tumors larger than 1 cm increase the risk of CLNM. uCLND for tumors larger than 1 cm, bCLND for tumors larger than 2 cm can be considered. We believe that patients with unilateral CLNM also have an increased risk of contralateral metastasis.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251334884"},"PeriodicalIF":2.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of Aurora B expression in cancer patients: A meta-analysis.","authors":"Md Mojahidur Hasan, Sehreen Tory, Yusuf Kemal Arslan, Yasemin Saygideger, Yusuf Tutar","doi":"10.1177/03008916251343384","DOIUrl":"10.1177/03008916251343384","url":null,"abstract":"<p><strong>Background: </strong>Overexpression of Aurora B is linked to poor prognosis in various malignancies; however, its prognostic role remains debatable. Conducting a meta-analysis is essential to reach a definitive conclusion.</p><p><strong>Methods: </strong>Various databases were searched. Aurora B protein expression was assessed for prognostic significance using pooled hazard ratio (HR) with a 95% confidence interval (CI). Meta-regression and subgroup analysis identified the source of heterogeneity.</p><p><strong>Results: </strong>The study comprised 1384 cancer patients from 10 articles. The result with multivariate data (pooled HR=1.18, 95% CI= 0.71-1.95, p=0.52, I²=83%) and univariate data (pooled HR=1.81, 95% CI=0.92, 3.57, p=0.09, I²=89%) showed that increased Aurora B expression was not linked with poor overall survival (OS). Subgroup analysis showed that sample size, follow-up time, cut-off value, non-Chinese patients, antibody source were not associated with unfavorable OS.</p><p><strong>Conclusions: </strong>Aurora B expression could not be used as a prognostic marker in cancer.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"253-260"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}